**Friday, June 1**

**Session Title:** Hematologic Malignancies—Plasma Cell Dyscrasia  
**Session Type:** Oral Abstract Session  
**Date:** Fri, June 1  
**Location:** E450  
**Time:** 2:45 PM - 5:45 PM  
**Speaker Name:** Luciano J. Costa

- **3:57 PM – 4:09 PM**  
  *Abstract 8004* Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma.

---

**Session Title:** Immunotherapy for Oncogene-Driven Non-Small Cell Lung Cancer: Caution Indicated!  
**Session Type:** Clinical Science Symposium  
**Date:** Fri, June 1  
**Location:** Hall D1  
**Time:** 4:30 PM - 6:00 PM  
**Speaker Name:** Dong-Wan Kim, MD, PhD

- **4:42 PM – 4:54 PM**  
  *Abstract 9009* Safety and clinical activity results from a phase Ib study of alectinib plus atezolizumab in ALK+ advanced NSCLC (aNSCLC).

---

**Saturday, June 2**

**Session Title:** Genitourinary (Nonprostate) Cancer  
**Session Type:** Poster Session  
**Date:** Sat, June 2  
**Location:** Hall A  
**Time:** 8:00 AM - 11:30 AM  
**Speaker Name:** Arjun Vasant Balar, MD
• **Abstract 4523** Atezolizumab (atezo) in first-line cisplatin-ineligible or platinum-treated locally advanced or metastatic urothelial cancer (mUC): Long-term efficacy from phase 2 study IMvigor210. **Poster Board #349**

**Session Title:** Pediatric Oncology  
**Session Type:** Poster Session  
**Date:** Sat, June 2  
**Location:** Hall A  
**Time:** 8:00 AM - 11:30 AM  
**Speaker Name:** Ami Vijay Desai, MD, MSCE

• **Abstract 10536** Phase 1 study of entrectinib (RXDX-101), a TRK, ROS1, and ALK inhibitor, in children, adolescents, and young adults with recurrent or refractory solid tumors. **Poster Board #209**

**Sunday, June 3**

**Session Title:** Breast Cancer—Metastatic  
**Session Type:** Oral Abstract Session  
**Date:** Sun, June 3  
**Location:** Hall D2  
**Time:** 8:00 AM - 11:00 AM  
**Speaker Name:** Jose Baselga, MD, PhD, FASCO; Rebecca Alexandra Dent, MD

• **10:00 AM - 10:12 AM**  
  **Abstract LBA1006** Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER.

• **10:24 AM - 10:36 AM**  
  **Abstract 1008** Overall survival (OS) update of the double-blind placebo (PBO)-controlled randomized phase 2 LOTUS trial of first-line ipatasertib (IPAT) + paclitaxel (PAC) for locally advanced/metastatic triple-negative breast cancer (mTNBC).

**Session Title:** Genitourinary (Nonprostate) Cancer  
**Session Type:** Oral Abstract Session  
**Date:** Sun, June 3  
**Location:** Arie Crown Theater  
**Time:** 8:00 AM - 11:00 AM  
**Speaker Name:** Bernard Escudier, MD; Thomas Powles, MD

• **8:24 AM - 8:36 AM**  
  **Abstract 4511** Patient-reported outcomes (PROs) in IMmotion151: Atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun) in treatment (tx) naive metastatic renal cell carcinoma (mRCC).
• 10:00 AM - 10:12 AM
  **Abstract 4506** A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in muscle invasive bladder cancer (ABACUS).

**Session Title:** Gastrointestinal (Noncolorectal) Cancer  
**Session Type:** Poster Session  
**Date:** Sun, June 3  
**Location:** Hall A  
**Time:** 8:00 AM - 11:30 AM  
**Speaker Name:** Stacey Stein, MD

• **Abstract 4074** Safety and clinical activity of 1L atezolizumab + bevacizumab in a phase Ib study in hepatocellular carcinoma (HCC). **Poster Board #263**

**Session Title:** Lung Cancer—Non-Small Cell Metastatic  
**Session Type:** Poster Session  
**Date:** Sun, June 3  
**Location:** Hall A  
**Time:** 8:00 AM - 11:30 AM  
**Speaker Name:** D. Ross Camidge, MD, PhD; Martin Reck, MD, PhD

• **Abstract 9043** Updated efficacy and safety data from the global phase III ALEX study of alectinib (ALC) vs crizotinib (CZ) in untreated advanced ALK+ NSCLC. **Poster Board #366**  
• **Abstract 9047** Patient-reported outcomes (PROs) in the randomized, phase III IMpower150 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous metastatic NSCLC (mNSCLC). **Poster Board #370**

**Session Title:** Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia  
**Session Type:** Oral Abstract Session  
**Date:** Sun, June 3  
**Location:** E450  
**Time:** 9:45 AM - 12:45 PM  
**Speaker Name:** Laurie Helen Sehn, MD, MPH; Peter Hillmen, M.B., Ch.B.

• **11:45 AM - 11:57 AM**  
  **Abstract 7507** Randomized phase 2 trial of polatuzumab vedotin (pola) with bendamustine and rituximab (BR) in relapsed/refractory (r/r) FL and DLBCL.

• **11:57 AM - 12:09 PM**  
  **Abstract 7508** High, durable minimal residual disease negativity (MRD−) with venetoclax + rituximab (VenR) in relapsed/refractory (R/R) CLL: MRD kinetics from phase 3 MURANO study.
Session Title: Plenary Session Including the Science of Oncology Award and Lecture
Session Type: Plenary Session
Date: Sun, June 3
Location: Hall B1
Time: 1:00 PM - 4:00 PM
Chair and/or Co-Chairs: Bruce E. Johnson, MD, FASCO; Ann H. Partridge, MD, MPH, FASCO; Daniel F. Hayes, MD, FACP, FASCO, BA; Douglas R. Lowy, MD; Joseph A. Sparano, MD; Lisa A. Carey, MD; Gianni Bisogno, MD; Douglas S. Hawkins, MD; Arnaud Mejean, MD, PhD; Daniel J. George, MD; Gilberto Lopes, MD, MBA; Leena Gandhi, MD, PhD

Monday, June 4

Session Title: Lung Cancer—Non-Small Cell Metastatic
Session Type: Oral Abstract Session
Date: Mon, June 4
Location: Hall B1
Time: 3:00 PM - 6:00 PM
Speaker Name: Robert M. Jotte, MD, PhD; Mark A. Socinski, MD

- 3:00 PM - 3:12 PM
  Abstract LBA9000 IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC.

- 3:45 PM - 3:57 PM
  Abstract 9002 Overall survival (OS) analysis of IMpower150, a randomized Ph 3 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous (NSQ) NSCLC.

Session Title: Targeted Therapy in Leukemia
Session Type: Clinical Science Symposium
Date: Mon, June 4
Location: E450
Time: 4:30 PM - 6:00 PM
Speaker Name: Courtney Denton Dinardo, MD

- 5:06 PM - 5:24 PM
  Abstract 7010 Durable response with venetoclax in combination with decitabine or azacitadine in elderly patients with acute myeloid leukemia (AML).
Tuesday, June 5

Session Title: Tumor Biology
Session Type: Oral Abstract Session
Date: Tue, June 5
Location: S406
Time: 8:00 AM - 11:00 AM
Speaker Name: Fatema A. Legrand, PhD; Vamsidhar Velcheti, MD; Gracy Crane

- 8:00 AM - 8:12 AM
  Abstract 12000 Association of high tissue TMB and atezolizumab efficacy across multiple tumor types.

- 8:12 AM - 8:24 AM
  Abstract 12001 Prospective clinical evaluation of blood-based tumor mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC): Interim B-F1RST results.

- 10:00 AM – 10:12 AM
  Abstract 12006 Application of a real world endpoint to identify and characterize genetic profiles of patients (pts) with poor prognosis in advanced non-small–cell lung cancer (aNSCLC).